Use of risperidone in psychotic disorder following ischemic brain damage.
Risperidone, a novel atypical neuroleptic agent, was used to treat a psychotic disorder secondary to ischemic brain damage in a 19-year-old adolescent, who had been treatment-refractory to two conventional antipsychotic agents and valproate. Clinically significant reductions in behavioral agitation and psychotic thinking initially appeared within the first 4 days of treatment with risperidone 3 mg twice daily. Risperidone was well tolerated despite this adolescent's severe cardiac and pulmonary illnesses. There was no evidence of increased neurotoxic symptoms in the presence of the ischemic brain damage. With its favorable side effect profile, risperidone may hold promise in the treatment of patients with psychotic disorders due to general medical conditions.
Zimnitzky
B M
BM
Department of Psychiatry, Children's Hospital, Boston, Massachusetts,
DeMaso
D R
DR
Steingard
R J
RJ
D000328:Adult; D002545:Brain Ischemia / Q000150:complications*; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010546:Perphenazine / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000209:etiology; D018967:Risperidone / Q000627:therapeutic use*
D010546:Perphenazine; D006220:Haloperidol; D018967:Risperidone